Prof. Lung Yi Mak

MD, FRCP

Dr Mak Lung-Yi, Loey is a Clinical Assistant Professor at the University of Hong Kong. She is a specialist in gastroenterology and hepatology. Dr Mak’s research interests include chronic viral hepatitis and steatotic liver disease. She has published more than 160 peer-reviewed articles in reputable journals, with >80 being first-authored/ co-first/ corresponding authored articles (H-index by Scopus: 35). Dr. Mak has received numerous academic awards, highlight being The Emerging Leader Award by The European Association for the Study of Liver, of which Dr. Mak is the first Chinese woman to receive this award. She was awarded the runner-up of The Rising Star Award for Global Women in Healthcare Awards by EMMS International in association with the Royal College of Physicians of Edinburgh in 2025. To recognise her major contribution to advancing human health and community service, Loey is selected to receive the Ten Outstanding Young Persons of Hong Kong in 2024. Dr. Mak is Associate Editor of Clinical Molecular Hepatology, and Editorial Board member for Journal of Hepatology and Hepatology Communications.

Prof. Norah Terrault

MD, MPH

Dr. Norah Terrault is a transplant hepatologist, the Neil Kaplowitz Professor of Medicine and Chief of Gastrointestinal and Liver Diseases Division at the Keck School of Medicine of University of Southern California in Los Angeles, California.

Dr. Terrault has focused her clinical and research activities on viral hepatitis and fatty liver disease, with specific focus on patients with cirrhosis and liver transplant recipients. In addition to multiple clinical trials related to preventing and treating chronic hepatitis viral hepatitis and fatty liver, Dr. Terrault has been PI on multiple NIH-funded studies, including the current NIH-supported HBV clinical research network (HBRN), nonalcoholic steatohepatitis clinical research network (NASH CRN) and Liver Cirrhosis Network (LCN). She has authored over 400 peer-reviewed manuscripts, editorials, invited reviews as well as US national guidelines for treatment of chronic hepatitis B and C and reproductive health. Dr. Terrault served as the 2023 AASLD President.

Prof. Wei Lai

Prof. Lai Wei is a Professor of Hepatology & Medicine, and is the Director of the Hepatobiliary and Pancreatic Center at Beijing Tsinghua Changgung Hospital. His current research interests involve antiviral treatment of hepatitis B and C. Prof. Wei is the President of the Chinese Society of Hepatology. He served to develop the Chinese Guideline for Management of Hepatitis B, and Management, Diagnosis and Prevention of Hepatitis C virus Infection. In addition, Prof Wei is involved in Kidney Disease Improving Global Outcome to develop a Guideline for HCV Infection, Diagnosis, Prevention and Management in Kidney Disease and contributes to APASL for hepatitis C guideline.

Prof. Jungqi Niu

Niu Junqi, M.D., is a Professor of Internal Medicine and Vice Dean of the Institute of Translational Medicine at the First Hospital of Jilin University. He holds multiple prestigious positions including Director of the Center for Infectious Diseases and Pathogenic Biology, Director of Jilin Provincial Institute of Hepatology, and Editor-in-Chief of the Journal of Clinical Hepatobiliary Diseases. Recognized as a Tang Aoqing Distinguished Professor at Jilin University.

With extensive experience in clinical research, Prof. Niu has led or participated in 145 new drug clinical trials, including:

• 34 international multicenter clinical studies
• 37 domestic multicenter phase III clinical studies (as principal investigator)
• 33 early-phase clinical studies (as lead researcher)
• 77 domestic multicenter clinical studies (as participating researcher)

His scholarly achievements include publishing over 200 peer on reviewed journal and SCI-indexed research papers and receiving numerous prestigious awards such as the Chinese Medical Science and Technology Award and the Ministry of Education’s Excellent Scientific Research Achievement Award.

Prof. Lim Seng Gee

Prof Lim Seng Gee currently serves as a Senior Consultant and Director of Hepatology at the Division of Gastroenterology and Hepatology, and a Senior Consultant at the Adult Liver Transplantation Programme, National University Centre for Organ Transplantation in National University Hospital, Singapore. He is an expert panel member, Centre for Drug Administration (CPA) and Centre for Drug Evaluation (CDE) at the Ministry of Health, Singapore and the Chairman of Singapore Hepatitis Conference since 2014. He is also a Professor in the Yong Loo Lin School of Medicine, National University of Singapore.

Prof Lim attained his basic medical degree with honours (MBBS Hons) from the University of Monash, Melbourne, Australia. He later pursued a doctorate degree (MD) in Monash and was awarded the FRACP (Australia), FRCP (London), FAMS (Gasteroenterology, Singapore).

He is considered a master clinician having trained over 40 gastroenterologists and hepatologists, and is regularly referred difficult to treat liver cases. His main clinical work focuses on the treatment of viral hepatitis (esp. B and C), liver disease and liver cancer.

Prof Lim’s research activities include leadership in Hepatology research, which focuses on improving treatment for chronic hepatitis B and C, pathophysiology of hepatitis B disease, HBV virology, immunological mechanisms of HBeAg seroconversion, and loss of immune tolerance to hepatitis B virus. He also has an interest in pathophysiology and treatment of liver cancer, primary hepatocyte culture, hepatocyte function, drug related liver disease and non-alcoholic fatty liver disease.

Prof Lim has over 253 publications in peer-reviewed journals with a H-index of 51, and sits on the editorial board of Liver International Hepatology, International, J Viral Hepatitis, Alimentary Pharmacology and Therapeutics, and Lancet Gastroenterology and Hepatology. He has received over S$48 million in research grants.

Prof Lim also sits on the Advisory Board of Novartis Pharmaceuticals, Idenix Pharmaceuticals, Bristol Myers Squibb Pharmaceuticals and is on the Speaker’s Bureau for GlaxoSmithKline and Schering Plough Pharmaceuticals. Prof Lim has been an invited speaker at AASLD, EASL and APASL in 2013, 2014 and is a regular speaker at numerous International and Regional meetings on liver disease and viral hepatitis.

Prof Lim is also an Evidence Based Medicine (EBM) Champion, having founded the annual Asia Pacific EBM workshop in 2004 together with Prof Tony Dans from the Philippines which still runs yearly, and actively teaches and contributes to the development of EBM in Singapore.

Prof Lim is Council member, International Coalition for Eradication of Hepatitis B Virus (ICE-HBV), AASLD Asia Pacific Regional Council member, Co-chair ICE-HBV treatment subcommittee, and Co-chair combination therapy subcommittee HBV Forum.

Prof. Massimo Levrero

Professor of Medicine, Sapienza University, Centre de Recherche en Cancerologie de Lyon (CRCL) Lyon, France

Massimo Levrero is Professor of Medicine at the University Claude Bernard Lyon 1 (UCLB1), Lyon, France, and Praticien Hospitalier in the Service d’Hepatologie et Gastroenterologie – Hopital de la Croix Rousse – Hospices Civils de Lyon. He leads a Research Unit on” Epigenetics and Epigenomics of Hepatocellular Carcinoma”, at the Centre de Recherche en Cancérologie de Lyon (CRCL) – INSERM U1052 in Lyon, France. He also serves as Associate Member at the IIT – Sapienza Center for Life NanoScience (CLNS) in Rome and he is on leave of absence from the Department of Internal Medicine (DMISM) at the Sapienza University of Rome, where he had his research activity and academic practice in hepatology until 2014.

Professor Levrero trained and completed his residency at Sapienza before holding posts at the University Paris VI and the Institut Gustave Roussy in Paris. He has acted as Scientific Secretary of EASL (European Association for the Study of the Liver) and he currently presides the CSS12 study session on basic and translational research on viral hepatitis at the French National Agency for Research on AIDS and Viral Hepatitis (ANRS). He is a founding member and seats in the Governing Board of ICE (International Coalition to Eliminate HBV).

He is actively involved in clinical research and treatment of HBV and HCV chronic hepatitis, and he served as Network Coordinator and/or Primary Investigator in a number of research projects and clinical studies. HBV research focuses on the epigenetic regulation of cccDNA function and HBV replication, the identification of new targets for anti-¬‐viral therapy and on liver oncogenesis in HBV-¬‐ related hepatocellular carcinoma. Additional research interests include signal transduction and transcription in the liver; IFN transcriptome; chromatin modifiers in solid tumours development and progression.

Professor Levrero is the author of over 200 publications in peer-reviewed journals, including Nature, Nature Medicine, Nat Cell Biol, Nature Communications, Science, J Clin Invest, J Exp Med, Mol Cell, PNAS USA, Cancer Res, Oncogene, EMBO J, J Biol Chem, Sci Rep, Gastroenterology, J of Hepatology, GUT, Hepatology, J of Virology, Virology, J Gen Virol, J Infect Dis, Blood.

Prof. MF Yuen

Chair of Gastroenterology and Hepatology

Professor Yuen is now the Chair Professor of The University of Hong Kong and Li Shu Fan Medical Foundation Professor in Medicine, and the Chief of the Division of Gastroenterology and Hepatology, Queen Mary Hospital, Hong Kong. He obtained his first bachelor’s degree of medicine in 1992. He further pursued his academic excellence through the achievement of obtaining three doctoral degrees including Doctor of Medicine with Sir Patrick Manson Gold Medal in 2001, Doctor of Philosophy in 2005 and Doctor of Science in 2017. Professor Yuen’s research interests include prevention, natural history, serology, virology and treatment of chronic hepatitis B and C, and hepatocellular carcinoma.

He is one of the top internationally renowned researchers in the field of hepatitis B disease. He has now published more than 630 papers in world-renowned medical journals including New England Journal of Medicine, Lancet, Nature Medicine, Lancet Infectious Diseases and Lancet Oncology. He has delivered more than 360 lectures all over the world.

Professor Yuen is now leading most of the international trials examining new drugs including antiviral and immunomodulatory agents for the treatment of chronic hepatitis B. He is also actively performing cutting-edge research on novel markers for hepatitis B infection and occult hepatitis B infection. With all these international academic and professional achievements, Professor Yuen is an invited member serving as key opinion leader for several international coalition committees including the International Coalition to Eliminate HBV (ICE-HEP) and Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) on hepatitis B disease. He is also serving as a member of Asia Pacific (APAC) Liver Disease Alliance and a member of Advisory Council of The Hepatitis Fund of a Swiss-based foundation.